ADVANCE
the largest, prospective study ever in
11140 Type 2 diabetic patients
2,3
For full prescribing information, refer to package insert approved by the medical regulatory authority.
DIAMICRON MR 30mg Tablets.
Gliclazide 30mg. Reg. No. 35/21.2/0178.
Each DIAMICRON Modified Release 30mg tablet contains 30mg Gliclazide. PHARMACOLOGICAL CLASSIFICATION A21.2 Oral
Hypoglycaemics. PRODUCT REGISTRATION NUMBER 35/21.2/0178. NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE:
Servier Laboratories South Africa (PTY) LTD (Reg No. 72/14307/07). Devcon Park, 7 Autumn Street, Rivonia, 2128. Tel: +27(0)11 233-6000.
FAX: +27(0)11 233-6099.
References: 1. ADVANCE Collaborative Group NEJM 2008;358;2560-72
.
2. Study rationale and design of ADVANCE. Diabetologia 2001; 44:
1118-1120. 3. ADVANCE patient recruitment and characteristics of the study population at baseline. Diabetes Med 2005;22: 882-888.
* DIAMICRON MR based strategy.
A leading partner
in the field of diabetic research
MORE WITH
DIAMICRON MR
• Diamicron MR*
reduces serious diabetic complications
1
• Diamicron MR*
significantly reduces renal events by 21%
& macroalbuminuria by 30%
1
•
Diamicron MR*:
No weight gain & low hypoglycaemia
1
